One of the main causes of failure in the treatment of breast
cancer is the intrinsic presence of, or development of, drug
resistance by the cancer cells. Recent studies on the mechanisms of
cancer drug resistance have yielded important information
highlighting both how tumour cells may escape these therapeutic
constraints and that drug resistance may further impinge on tumour
cell functions that may ultimately promote an adverse cell
phenotype. New targets have been identified with potential
therapeutic applications in resistant breast cancer leading to the
subsequent evaluation of inhibitors of these targets in preclinical
studies. Importantly, there is increasing evidence from such
studies demonstrating the benefit of novel combination strategies
as potential avenues for future drug regimens.
Written by experts in the subject area, this book covers the
molecular details and functional consequences of endocrine
resistance in breast cancer with particular emphasis on the future
applications of novel drug combinations that may be utilized to
circumvent resistance and improve anti-tumour effects. This book
represents a timely publication in the field of breast cancer
research, providing current knowledge in the area of drug
resistance and will be important reading material for clinicians
and researchers alike.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!